{"id":371635,"date":"2025-07-28T15:30:27","date_gmt":"2025-07-28T15:30:27","guid":{"rendered":"https:\/\/humainhealthcare.com\/?p=371635"},"modified":"2025-07-28T15:36:00","modified_gmt":"2025-07-28T15:36:00","slug":"ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy","status":"publish","type":"post","link":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/","title":{"rendered":"Ipilimumabi: Ensimm\u00e4inen glioblastoomasta vapaa potilas neoadjuvantti-immunoterapian j\u00e4lkeen"},"content":{"rendered":"<p>Lontoo, 21. hein\u00e4kuuta 2025 \u2013 Uusi hoitomenetelm\u00e4 glioblastoomaan, aggressiivisimpaan primaariseen aivokasvaimeen, on her\u00e4tt\u00e4nyt innostusta l\u00e4\u00e4ketieteellisess\u00e4 yhteis\u00f6ss\u00e4 sen j\u00e4lkeen, kun ensimm\u00e4inen t\u00e4ydellinen remissio on raportoitu ipilimumabi-(Yervoy)-neoadjuvanttihoidon j\u00e4lkeen. Lokakuussa 2022 diagnosoitu potilas on pysynyt ilman merkkej\u00e4 taudista yli kaksi ja puoli vuotta ilman alun perin suunniteltua leikkausta.<\/p>\n\n\n\n<p>The NeAT-GLIO clinical trial, led by University College London Hospitals (UCLH), administers ipilimumab before radiotherapy and chemotherapy, with the aim of boosting the immune response in newly diagnosed patients. The initial case is that of 40-year-old Ben Trotman, who, after receiving immunotherapy and completing conventional treatment, showed complete tumor shrinkage on imaging, with no recurrence to date.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Alustavat tulokset ja kliininen n\u00e4kym\u00e4<\/strong><\/h2>\n\n\n\n<p>Vaikka tulos rajoittuu edelleen yhteen tapaukseen, se on merkitt\u00e4v\u00e4, kun otetaan huomioon glioblastooman eritt\u00e4in huono ennuste, jonka mediaani elinaika on 9\u201312 kuukautta. Varhainen interventio ipilimumabilla pyrkii aktivoimaan immuunij\u00e4rjestelm\u00e4n, kun potilaan toimintakyky on suotuisin, ennen kuin muiden hoitojen aiheuttamat vauriot tapahtuvat.<\/p>\n\n\n\n<p>Aivosy\u00f6p\u00e4 edustaa kiireellist\u00e4 kliinist\u00e4 tarvetta innovatiivisille hoitomuodoille: nykyiset hoitovaihtoehdot eiv\u00e4t ole juurikaan kehittyneet vuosikymmeniin. T\u00e4m\u00e4 alustava menestys tasoittaisi tiet\u00e4 laajennetulle tutkimukselle, johon osallistuu 16 potilasta 18 kuukauden aikana. Tutkimuksen rahoittajana toimii brittil\u00e4inen parlamentin j\u00e4sen Dame Siobhain McDonagh, joka aloitti tutkimuksen glioblastoomaan kuolleen sisarensa muistoksi.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Seuraukset ja seuraavat vaiheet<\/strong><\/h2>\n\n\n\n<p>\u2013 Paradigman muutos: Neoadjuvantti-immunoterapian soveltaminen glioblastoomaan voisi olla virstanpylv\u00e4s, joka k\u00e4\u00e4nt\u00e4\u00e4 perinteisen l\u00e4hestymistavan, jossa n\u00e4m\u00e4 hoidot varataan vasta my\u00f6hemmille vaiheille.<\/p>\n\n\n\n<p>\u2013 Tulosten toistaminen: Laajennetun minitutkimuksen on varmistettava, voidaanko yksitt\u00e4inen tapaus toistaa pieness\u00e4, heterogeenisess\u00e4 kohortissa.<\/p>\n\n\n\n<p>\u2013 J\u00e4ljell\u00e4 olevat haasteet: On eritt\u00e4in t\u00e4rke\u00e4\u00e4 seurata toksisuutta, arvioida pitk\u00e4aikaisvastetta ja m\u00e4\u00e4ritell\u00e4 markkereita, jotka tunnistavat t\u00e4lle strategialle alttiimmat potilaat.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Johtop\u00e4\u00e4t\u00f6s<\/strong><\/h2>\n\n\n\n<p>Odotellessamme tuloksia useammilla potilailla, t\u00e4m\u00e4 tapaus on toiveikas virstanpylv\u00e4s: neoadjuvantti immunoterapia voi mullistaa glioblastooman hoitomenetelm\u00e4n. Jos n\u00e4m\u00e4 tulokset vahvistetaan, voidaan aloittaa uusi kliininen polku kasvaimelle, joka on aiemmin ollut haavoittumaton hoidoille.<\/p>","protected":false},"excerpt":{"rendered":"<p>London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":371636,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-371635","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-geneva"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"info@humainhealthcare.com\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Humain Healthcare: - Medical Treatment in\u00a0Barcelona\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:\" \/>\n\t\t<meta property=\"og:description\" content=\"London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1216\" \/>\n\t\t<meta property=\"og:image:height\" content=\"832\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-07-28T15:30:27+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-07-28T15:36:00+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/HumainHealthcareBarcelone\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:\" \/>\n\t\t<meta name=\"twitter:description\" content=\"London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#blogposting\",\"name\":\"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:\",\"headline\":\"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy\",\"author\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/photo-new-4.jpg\",\"width\":800,\"height\":477},\"datePublished\":\"2025-07-28T15:30:27+00:00\",\"dateModified\":\"2025-07-28T15:36:00+00:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#webpage\"},\"articleSection\":\"Geneva\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/#listItem\",\"name\":\"Geneva\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/#listItem\",\"position\":2,\"name\":\"Geneva\",\"item\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#listItem\",\"name\":\"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#listItem\",\"position\":3,\"name\":\"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/category\\\/geneva\\\/#listItem\",\"name\":\"Geneva\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#organization\",\"name\":\"Humain Healthcare\",\"description\":\"International medical services provider in Barcelona offering personalized diagnosis, treatment coordination, and access to top specialists for global patients.\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/\",\"telephone\":\"+34611975260\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/WhatsApp-Image-2025-05-26-at-22.12.40_410869ab.jpg\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#organizationLogo\",\"width\":1024,\"height\":1024},\"image\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/HumainHealthcareBarcelone\",\"https:\\\/\\\/www.instagram.com\\\/humainhealthcare\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/\",\"name\":\"info@humainhealthcare.com\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#authorImage\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/litespeed\\\/avatar\\\/767cd8d416ab6b3ab02867bd8bcdbb54.jpg?ver=1790180516\",\"width\":96,\"height\":96,\"caption\":\"info@humainhealthcare.com\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#webpage\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/\",\"name\":\"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:\",\"description\":\"London, July 21, 2025 \\u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/author\\\/infohumainhealthcare-com\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/photo-new-4.jpg\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#mainImage\",\"width\":800,\"height\":477},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\\\/#mainImage\"},\"datePublished\":\"2025-07-28T15:30:27+00:00\",\"dateModified\":\"2025-07-28T15:36:00+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/\",\"name\":\"Humain Healthcare:\",\"description\":\"Medical Treatment in\\u00a0Barcelona\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/humainhealthcare.com\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:","description":"London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a","canonical_url":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#blogposting","name":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:","headline":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy","author":{"@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author"},"publisher":{"@id":"https:\/\/humainhealthcare.com\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/photo-new-4.jpg","width":800,"height":477},"datePublished":"2025-07-28T15:30:27+00:00","dateModified":"2025-07-28T15:36:00+00:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#webpage"},"isPartOf":{"@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#webpage"},"articleSection":"Geneva"},{"@type":"BreadcrumbList","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr#listItem","position":1,"name":"Home","item":"https:\/\/humainhealthcare.com\/fr","nextItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/#listItem","name":"Geneva"}},{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/#listItem","position":2,"name":"Geneva","item":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/","nextItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#listItem","name":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy"},"previousItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#listItem","position":3,"name":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy","previousItem":{"@type":"ListItem","@id":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/#listItem","name":"Geneva"}}]},{"@type":"Organization","@id":"https:\/\/humainhealthcare.com\/fr\/#organization","name":"Humain Healthcare","description":"International medical services provider in Barcelona offering personalized diagnosis, treatment coordination, and access to top specialists for global patients.","url":"https:\/\/humainhealthcare.com\/fr\/","telephone":"+34611975260","logo":{"@type":"ImageObject","url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-26-at-22.12.40_410869ab.jpg","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#organizationLogo","width":1024,"height":1024},"image":{"@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/HumainHealthcareBarcelone","https:\/\/www.instagram.com\/humainhealthcare"]},{"@type":"Person","@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author","url":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/","name":"info@humainhealthcare.com","image":{"@type":"ImageObject","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#authorImage","url":"https:\/\/humainhealthcare.com\/wp-content\/litespeed\/avatar\/767cd8d416ab6b3ab02867bd8bcdbb54.jpg?ver=1790180516","width":96,"height":96,"caption":"info@humainhealthcare.com"}},{"@type":"WebPage","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#webpage","url":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/","name":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:","description":"London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/humainhealthcare.com\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#breadcrumblist"},"author":{"@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author"},"creator":{"@id":"https:\/\/humainhealthcare.com\/fr\/author\/infohumainhealthcare-com\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/photo-new-4.jpg","@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#mainImage","width":800,"height":477},"primaryImageOfPage":{"@id":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/#mainImage"},"datePublished":"2025-07-28T15:30:27+00:00","dateModified":"2025-07-28T15:36:00+00:00"},{"@type":"WebSite","@id":"https:\/\/humainhealthcare.com\/fr\/#website","url":"https:\/\/humainhealthcare.com\/fr\/","name":"Humain Healthcare:","description":"Medical Treatment in\u00a0Barcelona","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/humainhealthcare.com\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Humain Healthcare: - Medical Treatment in\u00a0Barcelona","og:type":"article","og:title":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:","og:description":"London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a","og:url":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/","og:image":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg","og:image:secure_url":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg","og:image:width":1216,"og:image:height":832,"article:published_time":"2025-07-28T15:30:27+00:00","article:modified_time":"2025-07-28T15:36:00+00:00","article:publisher":"https:\/\/www.facebook.com\/HumainHealthcareBarcelone","twitter:card":"summary_large_image","twitter:title":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy - Humain Healthcare:","twitter:description":"London, July 21, 2025 \u2013 A new therapeutic approach for glioblastoma, the most aggressive primary brain tumor, is generating excitement in the medical community after the first complete remission was recorded following neoadjuvant treatment with ipilimumab (Yervoy). The patient, diagnosed in October 2022, has remained without evidence of disease for more than two and a","twitter:image":"https:\/\/humainhealthcare.com\/wp-content\/uploads\/2025\/07\/twocaucasian.jpg"},"aioseo_meta_data":{"post_id":"371635","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-07-28 15:30:28","updated":"2025-09-26 14:07:59","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/humainhealthcare.com\/fr\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/\" title=\"Geneva\">Geneva<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tIpilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/humainhealthcare.com\/fr"},{"label":"Geneva","link":"https:\/\/humainhealthcare.com\/fr\/category\/geneva\/"},{"label":"Ipilimumab: First Patient Free of Glioblastoma After Receiving Neoadjuvant Immunotherapy","link":"https:\/\/humainhealthcare.com\/fr\/ipilimumab-first-patient-free-of-glioblastoma-after-receiving-neoadjuvant-immunotherapy\/"}],"_links":{"self":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts\/371635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/comments?post=371635"}],"version-history":[{"count":2,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts\/371635\/revisions"}],"predecessor-version":[{"id":371642,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/posts\/371635\/revisions\/371642"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/media\/371636"}],"wp:attachment":[{"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/media?parent=371635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/categories?post=371635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/humainhealthcare.com\/fr\/wp-json\/wp\/v2\/tags?post=371635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}